The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2022 | Treatments for HER2+ esophagogastric cancer
Per Pfeiffer, MD, PhD, Odense University Hospital and University of Southern Denmark, Odense, Denmark, discusses recent research into treatments for patients with HER2+ esophagogastric cancer, including the approval of trastuzumab plus chemotherapy. Prof. Pfeiffer emphasises the promising future of combination immunotherapy and chemotherapy for these patients. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
